drugset / Trial / NCT07451795
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy of SHR-1701 in combination with SBRT in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Timeline
- Start
- 2026-03-02
- Primary completion
- 2028-03-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 30 mg/kg | Intravenous |